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Use of Antibiotics and Development of Antibiotic Resistance 
 Commercial antibiotic drugs have been an effective tool for physicians in the treatment of 
bacterial infections for over 75 years. They have decreased the prevalence of human mortality as 
a result of bacterial infection and have improved the quality of life for many patients with access 
to these commercial treatments. In 1928 Alexander Fleming discovered penicillin.1 After his 
discovery, the introduction of the first commercially available antimicrobial agents—
sulfonamides specifically—in 1937 has enabled the treatment of once terminal infections.1 
However, there has been a steady rise in the prevalence of antibiotic resistance in bacteria that 
are subjected to treatment by these agents, which has begun to complicate the treatment of 
bacterial infections.1 
 As bacteria evolve alongside the development of new antibiotic drugs, mechanisms of 
antibiotic resistance have been seen in bacteria both pathogenic and nonpathogenic to humans 
due to the selective pressure placed on bacteria treated with commercial antibiotics.2 The 
selective pressure placed on bacteria is compounded by the overuse and misuse of commercially 
available antibiotics. Thirty percent to 50% of all cases of antibiotic prescriptions in the United 
States are incorrect in their treatment indication, choice of agent, or duration of therapy.3Also, 
30% to 60% of all antibiotics prescribed to patients in American Intensive Care Units have been 
deemed unnecessary, inappropriate, or suboptimal.3 It has been observed that the instances of 
antibiotic resistant bacterial infections increase in conjunction with increases in the number of 
antibiotics prescribed. This observation has been supported by the disparity in the abundance of 
antibiotic resistant infections between Northern European countries that prescribe fewer 
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antibiotics on average to the countries which occupy the Eastern and Southern regions of the 
continent which prescribe more antibiotics on average.4  
Additionally, antibiotics are commonly used in livestock production as a preventative 
therapy and promote the gain of additional mass in livestock animals. In the United States, it is 
estimated that 80% of the antibiotics purchased are used on livestock.3 By subjecting the 
livestock microflora to sustained levels of antibiotic drugs, resistant strains of bacteria are highly 
selected for. This promotion of resistant strains of bacteria within livestock has implications for 
people who consume the meat produced under these conditions. The consumer may be exposed 
to resistant strains of bacteria still present within the meat or to the residual antibiotics which 
were present in the animal upon processing. The sub-inhibitory levels of antibiotics to which the 
microflora of consumers are exposed can promote the development of resistance by supporting 
changes in gene expression, gene alteration, Horizontal Gene Transfer, and mutagenesis.3  
 As antibiotic resistant human pathogens become a more pressing issue, it has become 
increasingly complicated to treat infections once considered benign. Bacteria are able to survive 
treatment by antibiotics by employing numerous mechanisms. Bacteria may exhibit lower 
permeability to antibiotic compounds which can occur as the result of alteration in the number or 
selectivity of porin proteins within the cell wall. This has implications for a broad range of 
antibiotic drugs.5 Increases in efflux pumps within the bacterial cell membrane, including 
multidrug resistant efflux pumps, allow some bacteria to decrease cellular concentrations of the 
antibiotic, thereby rendering them ineffective.5 Some resistant species express alterations in 
target proteins which prevent the drug from binding.5 Hydrolysis has proven effective, especially 
against β-lactam drugs rendering drugs such as penicillin ineffective within the cell.5 Bacteria 
also exhibit a wide range of mechanisms that alter the chemical structure of the antibiotic 
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including acylation, phosphorylation, nucleotidylation, and ribitoylation which prevent the 
altered compound from binding to the target protein due to steric hindrance.5 A list of antibiotics, 
their targets, and the modes of bacterial resistance to the drug is presented in Table 1. 
 
Table 1: Commonly used antibiotic drugs, the target of their activity, and mechanisms of resistance 
which have arisen in bacteria.1 
These mechanisms enable bacteria to resist a wide variety of antibiotic drugs and in some 
cases may lead to multi-drug resistant strains which are increasingly difficult to treat. As a result, 
there has been a significant increase in reported deaths stemming from antibiotic resistant 
bacterial infections in the United States and throughout the world. In fact, the CDC estimated 
that in 2013 over 2 million people contracted antibiotic resistant bacterial infections resulting in 
23,000 reported deaths.6 In addition to the direct consequences of antibiotic resistance, the 
development of pan-resistant bacterial strains may render the ability to perform surgeries, organ 
transplantations, chemotherapy, and premature infant care impossible without inducing bacterial 
infections.7 As the number of antibiotic resistant pathogens rises it is imperative that new 
methods be developed to control these infections. 
Combating Antibiotic Resistance 
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 Aside from advocating for antibiotic stewardship among physicians, many areas of 
research are concerned with overcoming the mechanisms of antibiotic resistance which have 
arisen in recent years. Inhibiting the mechanism of resistance within the bacterial cell is one 
method which has received significant attention and produced some promising results. 
Preventing the action of bacterial enzymes which inactivate the drugs has led to the discovery of 
drugs, such as Clavulanic Acid, which inhibit β-lactamase activity and are effectively able to 
disrupt peptidoglycan synthesis.8 β-lactamases with active serine residues have also been found 
to be inhibited by boronic acids.9 Efflux pump inhibitors have been studied as a potential means 
for overcoming the ability of bacteria to drive out the intracellular antibiotics. They function by 
preventing the bacterial efflux pumps from functioning, thereby preventing them from 
decreasing cellular antibiotic levels.10  
 Bacteriophages offer another promising method for treating antibiotic resistant infections. 
The viral parasites which are used in phage therapy are highly specific, attacking only the target 
virulent bacterial species involved in the infection.7 This decreases the likelihood of secondary 
infections and protects the patient’s commensal flora unlike traditional antibiotics. 
Bacteriophages also replicate at the site of the infection, thus increasing their concentration in the 
areas they are needed unlike traditional antibiotics. However, the specificity of these 
bacteriophages makes them extremely narrow-spectrum, so this creates a need for definitive 
identification of the bacteria involved in the infection prior to the selection of a treatment. 
Making this identification has become increasingly accurate and expedient with the development 
of more efficient bedside molecular diagnostics; however, there are currently few countries 
engaging in the use of bacteriophages as a treatment for bacterial infections.7,11 
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 Enzymatic inhibition of bacterial growth is also an area of research which may help in 
addressing antibiotic resistance. Some success has been achieved in isolating and designing 
enzymes which have the ability to disrupt the normal functions of the bacterial cell. These 
enzymes are bactericidal and function by using catalytic mechanisms to degrade bacterial cell 
walls. Initial studies focused on endolysins contained within bacterial genomes and function in 
processes such as cell division in their wild type configuration.12 By engineering these 
endolysins to attack the bacteria from outside the cell, the potential for resistance is substantially 
decreased.12 Recently there has been some interest in using modified human lysozyme to evade 
the lysozyme specific inhibitory proteins of bacterial cells, enabling them to lyse the bacteria 
under conditions which the natural human lysozyme is ineffective.13 These enzymatic 
mechanisms for addressing antibiotic resistance are promising; however, clinically viable models 
have not currently been achieved. 
 The primary area of new antibiotic drug discovery involves synthetic tailoring of known 
chemical scaffolds to overcome mechanisms of resistance. Most of the clinically used antibiotics 
come from a relatively small set of chemical structures which have been extended by 
modification of their structures to improve their effectiveness.14 The altered chemical structures 
can improve the ability of a drug to avoid bacterial defenses such as catalytic enzymes or efflux 
pumps by exploiting the substrate specificity of these defense mechanisms.14 Because many of 
the chemical libraries which are popular among pharmaceutical companies are populated with 
compounds which are favored for human bioactivity, production of completely synthetic 
chemical entities which display inhibitory activity against bacterial cells is difficult due to the 
disparities between bacterial cells and eukaryotic cells.11 
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 Though synthetic tailoring has produced generations of antibiotic drugs which are 
effective against resistant bacterial strains by enabling them to avoid bacterial defenses, it is 
often a short-term solution. These new generations of semi-synthetic antibiotics retain the same 
core chemical scaffold and inhibit bacterial growth via the same mechanism as the original 
drug.14 The activity of these drugs is often not sustainable as bacteria develop mechanisms to 
overcome the synthetic alterations to the drug which are meant to restore the drug’s activity.14 
Discovering new chemical scaffolds would perhaps be a more sustainable method for 
overcoming resistance in pathogen bacteria because it would increase the diversity of 
mechanisms of inhibition, and it would provide a broader range of chemical scaffolds which 
could be synthetically tailored.14 
Natural Products 
 One promising avenue for the discovery of novel chemical scaffolds is by isolating the 
natural organic products of living organisms. Natural products and their semi-synthetic 
derivatives account for over two-thirds of all clinically-approved antibiotic drugs.14 The term 
natural product is used broadly to refer to all organic products produced by a living organism to 
ensure its survival and increase its fitness. The organic products which are produced by living 
organisms are divided into three broad yet distinct groups. Products which play a central role in 
the metabolism and reproduction of the cell such as nucleic acids, amino acids, and sugars are 
primary metabolites.15 High-molecular-weight polymeric compounds such as lignins, cellulose, 
and proteins, are responsible for the formation of the cellular structure.15  
Secondary metabolites have biological effects on other cells or even other organisms.16 
These metabolites may function in regulation, signaling, and defense against other organisms.15 
The ability of an organism to produce secondary metabolites is an adaptive characteristic which 
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confer a biological advantage upon the organism, increasing its survival and ability to reproduce. 
Secondary metabolites fall into several categories including terpenoids and steroids, 
phenylpropanoids, alkaloids, specialized amino acids and peptides, specialized carbohydrates, 
and polyketides.15 They are differentiated from primary metabolites based on their functionality 
rather than structure.17 Due to the bioactivity of secondary metabolites on other organisms, they 
have been an area of intense interest. In fact, it is estimated that over 40% of all medicines 
originated from secondary metabolites.15 Some bacterial secondary metabolites have the key 
function of inhibiting the growth of other bacterial species making them prime candidates for the 
discovery of novel antibiotic drugs.15 It has been estimated that over 45% of medically important 
antibiotics have been obtained from the order Actinomycetales.18 
The Genus Rhodococcus 
 Rhodococcus is a genus of Actinomycetes which are aerobic, Gram-positive, GC-rich, 
nonsporulating, and non-motile bacteria which contain mycolic acids in their cellular envelope.18 
Rhodococci have chemotype IV cell walls which are composed of meso-diaminopimelic acid 
containing peptidoglycan along with arabinose and galactose as the major sugars.17 Their cell 
morphology fluctuates throughout their growth cycle from the cocci configuration to short rods 
in some species and filamentous rods in other species.19 Some rods may even begin branching 
out in a simple or complex manner in some Rhodococcus species.19 Rhodococcus species can be 
found in soil, rocks, boreholes, groundwater, animal dung, insect guts, and in healthy or diseased 
plants and animals.20  
 Rhodococcus has proven useful in industry for its ability to degrade organic compounds, 
an ability which may be due in part to their mycolic acid containing cell walls which are 
proposed to allow the uptake of hydrophobic compounds.17 Genomic sequencing of a strain of 
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Rhodococcus RHA1 by McLeod et al. found that it contained protein-coding genes which were 
responsible for the production of 203 oxygenases and 192 ligases. Many of these are involved in 
pathways predicted to degrade aromatic compounds or steroids.21 This may contribute to the 
ability of RHA1 to degrade polychlorinated biphenyls (PCBs).21 Using a wide variety of 
enzymes, Rhodococci, have been successfully used in industry to degrade compounds by 
dehydrogenation, desulfurization, dehalogenation, epoxidation, hydrolysis, hydroxylation, and 
oxidation.18 The robust stress tolerance and rapid growth rates have also influenced the utility of 
Rhodococci in industry with applications in bioremediation and biocatalysis.17  
 The genus Rhodococcus is also notable for its ability to produce secondary metabolites, 
some of which have antimicrobial properties. The first antibiotic like compound discovered 
within the genus was found to inhibit the growth of fungal species Candida albicans and 
Cryptococcus neoforms, though it did not show antibacterial activity.22 Chiba et al. discovered 
five cyclic tetrapeptides produced by Rhodococcus sp. Mer-N1033—which were isolated from 
soil samples collected at Mt. Hayachine, Iwate Prefecture, Japan—and named these compounds 
rhodopeptin C1, C2, C3, C4, and B5. The chemical structure of these compounds can be seen in 
Figure 1. The cyclic tetrapeptide rhodopeptins were found to be composed of three α-amino 
acids and one lithophilic β-amino acid.22 They were found to be soluble in methanol, dimethyl 




Figure 1: Core Rhodopeptin Structure along with R groups which are characteristic of Rhodopeptins C1, 
C2, C3, C4, and B5.22 
 Another set of antimicrobial agents isolated from Rhodococcus were termed lariatins A 
and B. These compounds discovered by Iwatsuki et al. in 2007 and were isolated from 
Rhodococcus sp K01-B0171 which was collected in Yunnan, China. They were found to be 
cyclic peptides which consisted of 18 to 20 amino acid residues.23 These residues exhibited an 
internal linkage between the γ-carboxyl group of the Glu8 residue and the α-amino group of the 
Gly1 residue.23 The tail region of these cyclic peptides were found to pass through the ring 
region forming a “lasso” structure.23 The “lasso” structures of Lariatins A and B are show in 
Figure 2. Lariatins A and B were found to have inhibitory activity against Mycobacterium 
smegmatis while lariatin A also exhibited activity against Mycobacterium tuberculosis.23 The 
lariatin compounds were both found to be pale yellow solids at room temperature.23 The 
molecular weight of lariatin A was found to be 2050, and the molecular weight of lariatin B was 
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found to be 2204.23 These compounds were found to be soluble in water, methanol, and DMSO 
and insoluble in ethyl acetate and chloroform.23  
 
Figure 2: “Lasso” structure of lariatins A and B.23 
 Research by Kitagawa et al. focused on one strain of Rhodococcus erythropolis, 
identified by a larger study, which had been found to produce an inhibitory compound with a 
broad spectrum of activity against Gram-positive bacterial species and was able to elucidate the 
structure of the compound.24 It was found that the strain, Rhodococcus erythropolis JCM 6824, 
had a quinoline structure and a molecular weight of 395.24 The compound was termed aurachin 
RE.24 This compound was found to be highly similar to aurachin C, an antibiotic isolated from 
Stigmotella aurantiaca, a Gram-negative myxobacterium.24 The sole difference between the two 
compounds is the presence of a hydroxyl group on the hydrocarbon chain at the C-9’ position in 
aurachin RE rather than a hydrogen in aurachin C. Aurachin RE exhibited considerably stronger 
inhibitory activity than aurachin C which may be a result of the increase in solubility in the 
aqueous phase granted by the hydroxyl group.24 The hydroxyl group may also increase the 
ability of the compound to permeate the cell walls of Gram-positive bacteria.24 Aurachin RE was 
found to be a gray-brown powder which is soluble in ethanol, methanol, methyl cyanide, DMSO, 
ethyl acetate and moderately soluble in water.24 
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 Antibiotic compounds have also been isolated from Rhodococcus by employing 
horizontal gene transfer with other bacterial species. Kurosawa et al. subjected a multi-drug 
resistant strain of Rhodococcus fascians that does not produce an antibiotic compound and a 
susceptible strain of Streptomyces padanus which was a stable producer of the antibiotic 
actinomycin to competitive co-culturing techniques.25 A strain of Rhodococcus, termed 307CO, 
emerged from the culturing techniques and was found to produce two antibiotic compounds.25 
This strain of Rhodococcus was found to harbor a large segment of DNA derived from the 
Streptomyces strain indicating the occurrence of horizontal gene transfer.25 It was found that the 
production of the antibiotic compounds in Rhodococcus 307CO correlated with the presence of 
Streptomyces DNA within its genome.25 The two antibiotic compounds which were isolated from 
Rhodococcus 307CO were named rhodostreptomycin A and B and were found to be two isomers 
of a new class of aminoglycosides.25 Rhodostreptomycins A and B were found to have a broad 
spectrum of activity against both Gram-negative and Gram-positive bacterial species, though B 
was found to be slightly more potent than A. This suggests that the stereochemistry of the 
compound influences biological activity.25 The compounds were described as optically active 
white powders which were highly soluble in water but not chloroform or n-hexane.25  
Rhodococcus sp. MTM3W5.2 
 A strain of Rhodococcus, which was isolated from soil samples collected in Morristown, 
Tennessee in 2011, was found to have good antimicrobial activity against Rhodococcus 
erythropolis and other Rhodococcus and closely related species.19 The strain which produces this 
inhibitory compound was found to be similar to Rhodococcus jostii and most closely related to 
Rhodococcus opacus with 90% similarity; it was termed MTM3W5.2.26 The colonies of the 
strain were found to grow flat on the agar surface and were initially white, but obtained a tan 
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pigmentation as the culture aged.26 The initial white coloration and growth characteristics of the 
MTM3W5.2 colonies are depicted in Figure 3. The compound was initially produced at a 
temperature of 15°C but it was later found that the compound was also produced at temperatures 
of approximately 20°C.19 The gene cluster responsible for production of the inhibitory molecule 
was found to be similar to polyketide synthase gene clusters from Streptomyces and other 
Rhodococcus species.26  
 
Figure 3: Appearance of Rhodococcus sp. MTM3W5.2 colonies on an agar surface. Colonies are flat and 
spread over the agar. The colonies are initially white but turn tan in color with increasing age.19 
Polyketides 
 Polyketides are a subgroup of natural products which have a diverse range of structural 
and functional diversity.27 They have been observed to have a broad range of biological activities 
including antibacterial, antifungal, anticholesterol, antiparasitic, anticancer, and 
immunosuppressive properties.28 This structural and functional diversity is a product of 
combinatorial utilization and template-directed elongation of a few simple building blocks in a 
process similar to the synthesis of fatty acids.27 Synthesis of polyketides is conducted by 
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numerous Gram-positive bacteria which reside in soil such as species belonging to the order 
Actinomycetales including members of the genus Streptomyces and the genus Rhodococcus.28 
Some polyketide compounds have successfully been implemented as commercial antibiotic 
drugs including erythromycin and tetracycline which are broad spectrum drugs that inhibit 
bacterial protein synthesis.27  
Polyketide Synthases  
 The vast structural diversity of polyketide compounds arises from the coordinated, 
multistep action of enzymes organized in an assembly line like manner.28 Polyketide synthesis 
takes place through the addition of specific acyl originators, typically acetyl-CoA, malonyl-CoA 
or their derivatives, to a growing polyketide intermediate through decarboxylative Claisen 
condensation of thioester-activated acyl groups. After this process, the intermediate may undergo 
additional modification.28,29 Enzymes responsible for the construction of polyketide compounds 
are termed polyketide synthases (PKSs). These PKSs are mega enzyme-complexes which 
operate through the action of multiple functional subunits. These subunits, called modules, are 
composed of several domains, each of which has a specific enzymatic function which are 
arranged in a manner analogous to that of fatty acid synthases.29 There is a large assortment of 
domains which are involved in the synthesis of most polyketides. The domains which are 
obligatory for the synthesis of all polyketides are the acyltransferases (AT). AT selects the 
extender unit from a pool of CoA products and loads them onto an acyl-carrier protein (ACP) 
domain.29 A decarboxylative Claisen condensation reaction with the upstream intermediate is 
conducted by ketosynthase (KS). The acyl-carrier protein (ACP) acts as a carrier for the 
intermediates which are tethered to the synthase complex by a thioester linkage to the 
phosphopantetheine cofactor of the acyl-carrier protein.29 An example of the synthetic order of a 
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polyketide synthase is depicted in Figure 4. The compound may then undergo up to three 
reductive reactions which are carried out by the reductive domains ketoreductase (KR), 
dehydratase (DH), and enoyl-reductase (ER), yielding different degrees of reductions which may 
result in β-keto, β-hydroxy, α,β-alkene, or fully reduced intermediates.29 Upon completion of the 
catalytic activity of one module, the ACP region transfers the intermediate to the next module 
which will then add to the growing polyketide.29 Finally, the thioesterase (TE) domain allows the 
compound to dissociate from the ACP region of the final module, releasing the polyketide 
compound.29 Typically the number of precursors which are incorporated into the finished 
polyketide compound matches the number of modules which are required for its synthesis.27  
 
Figure 4: Arrangement of the polyketide synthase complex partially responsible for the synthesis of 6-
deoxyerythronide B (DEBS) depicting the arrangement of domains within each synthetic module.30  
Structural complexity is introduced into polyketide compounds as a result of the variation 
in stereochemistry and degree of reduction which takes place after each condensation reaction.31 
These factors are augmented by the ability of PKSs to conduct further downstream modification 
to the compound by enzymatically introducing cyclizations, oxidations, alkylations, 
glycosylations, methyl-transfer, halogenation, and β-branching.29,31 Additionally, many 
polyketide synthase gene clusters encode for enzymes which tailor the released polyketide into 
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the final biologically active natural product by employing reactions such as methylation, 
epoxidation, and hydroxylation.29 
 Polyketide synthases resemble fatty acid synthases in form and function. In fact, the type 
I PKS and metazoan type I fatty acid synthase (FAS-I) have been found to have a common 
evolutionary ancestor.29 They have homologous catalytic and ACP domains and both 
megasynthases have a common domain order.29 The striking similarities between the KS-AT di-
domains of PKS and KS-AT domain of FAS-I are perhaps the most substantial evidence for the 
commonality of architecture between the two megasynthases.29 While PKS and FAS often have 
the same precursor molecules which include acetate derivatives, the overall addition of the 
precursors to the growing intermediates takes place differently.15 In fatty acid synthesis, the 
carbonyl group of the acetate precursor unit is reduced during the chain assembly; whereas, the 
addition of precursor units in polyketide synthesis occurs through a mechanism of 
decarboxylative Claisen condensation followed by differing degrees of reduction of the keto 
groups of the resultant intermediate.15,29 Biosynthesis of fatty acids and polyketides also differ in 
the overall number of precursor molecules incorporated into the growing chain and cyclization of 
the final products.29   
 PKSs are arranged into three broad categories which are derived from the canonical 
differentiations between fatty acid synthases. Type I PKSs are multifunctional enzymes which 
are organized into modules and minimally contain an acyltransferase, ketosynthase, and an acyl-
carrier protein domain.32 Type I PKSs are further differentiated into modular type I PKSs, which 
are the classical bacterial type I PKS. It has modules that act non-iteratively and are responsible 
for the catalysis of one cycle of chain elongation.28 Iterative type I PKSs take advantage of the 
same catalytic domains, but all domains occur on a single polypeptide which is repetitively used 
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to generate the entire backbone of the polyketide compound.28 Type II PKSs are multifunctional 
enzyme complexes comprised of multiple enzymes which carry at minimum a single set of 
iteratively acting enzymes.33 Type II PKSs consist minimally of the core enzymes 
acyltransferase, acyl-carrier protein, and, contrary to type I PKSs, two ketosynthase regions.33 
This extra KS region denoted KSβ has been shown to lack an active cysteine; however, despite 
the lack of a cysteine active site, they have been shown to be involved. This suggests that they 
are not catalytically silent.33 Type III PKSs are often referred to as chalcone synthase-like 
PKSs.32 They are homodimeric enzymes that are iteratively acting condensing enzymes.32 Unlike 
type I and II PKSs, they act independently of acyl-carrier protein and instead act directly upon 
acyl-CoA precursors.32  
Current Work 
 The aim of this study is to identify the polyketide antibiotic compound produced by 
Rhodococcus sp. MTM3W5.2. This study details an efficient method for extracting the active 
metabolite from large batch broth cultures of the producer strain as well as an effective means for 
purifying the active metabolite using a combination of size exclusion chromatography and 
reversed-phase high-performance liquid chromatography (RP-HPLC). A description of the 
spectroscopic methods used to obtain data regarding the structural elucidation of the compound 
of interest is also included. The objectives of the project are to extract the active metabolite using 
the solvent extraction method set forth by Pushpavathi Manikindi, pre-fractionate the crude 
extract using size exclusion chromatography, isolate the inhibitory compound using semi-
preparative RP-HPLC, purify the inhibitory compound by employing an analytical HPLC 
column and appropriate HPLC purification method, analyze the compound using high-resolution 
17 
 





Materials and Methods 
Reagents 
 The reagents which were used throughout this study during the purification and 
characterization of the inhibitory compound are discussed below.  
HPLC Solvents 
 The purification and analysis of the inhibitory compound required the use of two 
different solvents which were used as the mobile phase. Throughout the study solvent A was 
consistently chosen to be deionized water which was obtained from an Elga PURELAB UHQ 
water purification system. Solvent B was selected to be HPLC-Grade acetonitrile (CH3CN) 
during most of the HPLC purification methods; however, HPLC-Grade methanol (CH3OH) was 
also used during some HPLC separation methods. To dissolve the crude Rhodococcus sp. 
MTM3W5.2, it was extracted prior to conducting HPLC purification and diluted before it was 
injected. HPLC-Grade 2-propanol, dimethyl sulfoxide (DMSO), chloroform, HPLC-Grade 
methanol, and ethanol were also used.  
HPLC Buffers 
 During the study two different buffers were used to improve the separation of the active 
compound during RP-HPLC purification. Ammonium formate (HCOONH4) was used at a 
concentration of 20mM, and ammonium hydroxide was used in concentrations of 0.01% and 
0.005%. 20mM ammonium formate was prepared by adding 0.63g of ammonium formate to 
5mL of deionized water and adding 495mL of deionized water for a total volume of 500mL. 
0.01% ammonium hydroxide solution was prepared by diluting 200µL of 50% ammonium 
hydroxide stock solution with 1L of deionized water.  
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Other Solvents and Reagents 
 During the liquid-liquid extraction of the Rhodococcus sp. MTM3W5.2 broth cultures, n-
butanol was used to obtain the inhibitory compound from the culture. HPLC-Grade methanol 
was used as the mobile phase during size exclusion chromatography. Dimethyl sulfoxide 
(DMSO), 2-propanol, ethanol, and chloroform were used to dissolve the inhibitory compound 
prior to HPLC analysis. 
Bacterial Strains and Growth Media 
Bacterial Strains 
The strain of Rhodococcus sp. MTM3W5.2, which was used throughout this study, was 
supplied by Dr. Bert Lampson of the East Tennessee State University Department of Health 
Sciences. It is a wild-type soil bacterium that produces an antimicrobial compound. It was 
isolated from a soil sample taken in Morristown, Tennessee in 2011.19 The other strain of 
bacteria used in this study Rhodococcus erythropolis IGTS8 is sensitive to the antimicrobial 
compound of interest and was used as an indicator of antimicrobial activity during the 
purification of the compound.  
Bacterial Growth Media 
 Rich media (RM) was employed during culturing of the MTM3W5.2 bacterial strain. 
Both RM broth and agar plates were used during the study. The RM broth was prepared by 
adding 5g of glucose, 4g of nutrient broth, and 0.25g of yeast extract to 500mL of water. The 
contents were then stirred and autoclaved at 121°C for 20 minutes. The agar plates were prepared 
using the same recipe and adding 7.5g of Bacto™ agar. The RM agar was autoclaved at 121°C 
for 20 minutes and cooled in a 55°C hot water bath before they were poured. Once the agar had 
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cooled, it was poured into 100mm x 15mm polystyrene Fisherbrand Petri dishes. They were 
allowed to cool and solidify overnight on a bench top. Afterwards, they were stored at 4°C for 
future use.26 
 Mueller-Hinton agar plates (MH) were used during zone inhibition assay to assess the 
activity of the crude MTM3W5.2 extract as well as the fractions taken during Sephadex LH-20 
column chromatography and HPLC. MH agar plates were created by dissolving 19.5 g of 
Difco™ Mueller-Hinton agar in 500 mL of distilled water while applying heat.26 The solution 
was then autoclaved at 121°C for 20 minutes. The medium was then cooled in a 55°C water bath 
after which time it was poured into sterile 100mm x 15mm polystyrene Fisherbrand Petri dishes. 
The MH agar plates were allowed to cool and solidify on a benchtop overnight. The solidified 
MH agar plates were then stored at 4°C for future use.26 
Extraction Methods 
 A method for culturing the Rhodococcus sp. MTM3W5.2 bacterial strain to ensure that 
sufficient production of the secondary metabolite of interest was adopted from Manikindi et al.17 
Since the production of secondary metabolites varies widely based on the type of medium used 
and the specific microorganism that is cultured, it was highly important to employ a culturing 
method which would ensure that significant production of the active metabolite took place. The 
solvent which was chosen for the solvent extraction method was vital in obtaining a sufficient 
amount of the inhibitory compound to allow further purification and analysis to be conducted. 
The solvent used was chosen based on polarity and was adopted from an extraction method 
described by Pushpavathi Manikindi.17 
RM Broth Culture Extraction of MTM3W5.2 Metabolites 
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The active metabolite of interest has been shown to be produced by Rhodococcus sp. 
MTM3W5.2 under stagnant growth conditions based on work by A. Ward.26 To produce a 
sufficient amount of the active metabolite for further purification and analysis, 2000 mL of RM 
broth was prepared. 500 mL portions of the RM broth were added to four 2 L Erlenmeyer flasks, 
shown in Figure 5. A seed culture of the MTM3W5.2 bacteria was created by adding 10 mL of 
RM broth to a test tube and inoculating it with the bacteria. The seed culture was incubated at 
27°C for 48 hours under constant shaking. After incubation, 2.5 mL portions of the seed culture 
were added to each of the flasks. The flasks were then incubated under stagnant conditions for 2 
weeks at 20°C. After growth, the bacterial cultures were added to centrifuge bottles and 
subjected to centrifugation at 6000 rpm for 10 minutes. The supernatant was added back to the 
flasks and the cells were disposed. 100 mL of n-butanol was added to the supernatant within 
each of the flasks. The flasks were then shaken in a floor incubator for 30 minutes at 100 rpm. 
After shaking, the cultures were added to separatory funnels and allowed to settle. The bottom 
aqueous layer was added back to the flasks and the top organic layer which contained the n-
butanol was retained. 50 mL portions of n-butanol were then added to each of the flasks 
containing the aqueous layer and the flasks were shaken for an additional 30 minutes. The 
solution was again added to the separatory funnel, and the organic layer was retained. The 
aqueous layer was disposed of. The n-butanol extract was then evaporated under a fume hood 




Figure 5: 2 liter Erlenmeyer flasks containing 500 mL of RM broth used in the growth of Rhodococcus 
MTM3W5.2 cultures. 
Zone Inhibition Antimicrobial Activity Assay 
 To determine whether the compound of interest had been isolated during the n-butanol 
extraction method and to determine which fractions contained active metabolites during 
Sephadex LH-20 column chromatography and HPLC, a zone inhibition assay was used. This test 
is conducted by soaking a paper disk with the antimicrobial compound and placing it on an agar 
plate which has been inoculated with a sensitive indicator bacterium. If the compound placed on 
the paper disk was inhibitory, it would prevent the growth of the indicator bacteria in the vicinity 
of the disk creating a zone of inhibition.  
 Initially, a seed culture of the sensitive indicator bacteria was created by adding 2 mL of 
RM broth to a 10 mL test tube. A well-formed and isolated colony of the indicator bacterium was 
selected from an agar plate of Rhodococcus erythropolis IGTS8 to ensure that no unwanted 
bacteria species contaminated the seed culture. The colony which was selected was used to 
inoculate the RM broth in the test tube by transferring the cells using a sterile loop. The seed 
culture was placed in a shaking water bath and incubated at 27°C for 18 hours. After suitable 
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turbidity was obtained, the seed culture was ready to inoculate the MH plates used in zone 
inhibition assay.  
 The MH agar plates were then inoculated with the indicator seed. This was accomplished 
by plunging a sterile cotton swab into the turbid R. erythropolis seed culture and rotating the 
swab several times while pressing on the inside wall of the test tube above the liquid level during 
removal of the swab to remove superfluous liquid. The swab was then swiped over the entire 
surface of the MH agar plate to create a sufficient bacterial lawn.  
 The compound was then added to the sterile paper disks prepared from Whatman blotting 
paper GB004 using a hole puncher. The newly punched paper disks were then autoclaved at 
121°C for 20 minutes to ensure sterilization. The paper disks were labeled using a pencil. After 
labeling, the disks were soaked with 25 µL of the crude extract of chromatographic fraction. The 
disks were allowed to completely absorb the liquid before adding an additional 25 µL of the 
compound to each disk. The total volume of compound added to each disk was 50 µL for the 
crude n-butanol extract and the Sephadex LH-20 fractions as well as most HPLC fractions. 
When the volume of HPLC fractions were low, indicating a higher concentration of compound 
within the fraction, a total volume of 25 µL was added to the paper disks to ensure the resolution 
of the zones of inhibition was sufficient to determine which fractions contained the active 
compound.  
 The dried paper disks were then added to the MH agar plate which was inoculated with 
the indicator bacteria. The disks were placed a sufficient distance apart to ensure that clear zones 
of inhibition could develop and were pressed down to ensure complete contact with the agar 
surface. After adding the disks, the plate was left to grow at room temperature for approximately 
48 hours before examining each plate for activity. The final plate showed a consistent bacterial 
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lawn of the indicator bacteria over the agar surface without the presence of individual colonies. If 
individual colonies were observed, the inoculum was not sufficiently concentrated, and the test 
was repeated. Zones of inhibition were noted by consistent circular areas surrounding a paper 
disk in which no indicator bacteria grew. 
Chromatographic Methods 
 This study involved multiple chromatographic steps to ensure that a highly pure sample 
of the inhibitory compound was obtained upon which spectral analysis could be conducted. The 
chromatographic methods are outlined below from preliminary purification of the crude extract 
to final HPLC purification. 
Size Exclusion Chromatography (SEC) 
 To ensure good separation of the compounds within the crude butanol extract, size 
exclusion chromatography was employed. This type of chromatography takes advantage of the 
size differences among molecules. By packing a chromatography column with the small, porous 
polymer beads of the stationary phase, the molecules in the crude extract are separated based on 
their ability to fit within the pores in the polymer beads.34 Large molecules are unable to enter 
into the pores of the medium and must pass directly through the interparticle volume of the 
medium causing it to elute more quickly; however, small molecules are able to enter into the 
pores of the medium and become trapped causing them to elute slower. This provided separation 
between compounds found within the sample.34 Sephadex™ LH-20 was selected as the 
chromatographic medium for this study based on its unique physico-chemical properties. 
Sephadex™ LH-20 resin is designed for use with polar organic solvents and aqueous solvent 
mixtures, making it useful for the isolation of the inhibitory compound of interest which has been 
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found to be soluble in the organic mobile phase used in SEC. The LH-20 resin is both 
hydrophilic and lipophilic causing it to swell in organic solvents. It is created by 
hydroxypropylation of a cross-linked dextran, Sephadex™ G-25.34 This cross-linking yields a 
polysaccharide network with pores with an average size of 103 µm in methanol.34 This allows 
for high resolution separation of the compounds in the crude extract and allows for good 
recovery of the compound of interest. Size exclusion chromatography relies on an isocratic 
elution method using a single constant mobile phase to elute the compounds within the crude 
extract. The size exclusion chromatography method used during this study was termed 
Sephadex™ LH-20 chromatography based on the medium used.  
Procedure: 
 28.78 g of Sephadex™ LH-20 dry powder was added to a 250 mL beaker and swollen in 
excess methanol for 2 hours. The beaker was stirred at 30-minute intervals to release any air 
bubbles which may have become trapped in the medium. The swollen slurry was added to a 
chromatographic column through a glass rod to ensure the column was filled evenly and no air 
bubbles were formed. After adding the medium to the column, the solvent reservoir was 
attached, and the methanol solvent was allowed to flow through the column with atmospheric 
pressure. After ensuring that the column was tightly packed with Sephadex™ resin and devoid of 
air bubbles, the stopcock was closed. The dried n-butanol crude extract was then reconstituted by 
adding 10 mL of isopropanol to the beakers containing the dried crude extract and shaking them 
for 4 hours at 100 rpm in a floor incubator. The extract was then added to the Sephadex column 
and eluted using methanol as the mobile phase. Pressure was applied to the column until a flow 
rate of approximately 2.5 mL/min was reached to ensure uniform elution of the active compound 
was achieved. The eluate was collected in 15 fractions of 50 mL, each of which were tested for 
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antimicrobial activity using zone inhibition assay. Fractions which demonstrated antimicrobial 
activity were pooled and dried under a fume hood.  
High-Performance Liquid Chromatography 
 HPLC is an effective means for purification of natural products and yields good 
separation between eluted compounds. HPLC employs the use of high solvent pressures to force 
the mobile phase and the sample through a column with small stationary phase particle sizes in a 
short, narrow column.35 By decreasing the particle size of the stationary phase the surface area of 
stationary phase is increased allowing more association between constituents of the sample with 
the stationary phase media which leads to more effective separation with a higher resolution than 
other liquid chromatographic techniques.35 The HPLC instrument, which was employed for the 
purification of the antimicrobial compound, was a Shimadzu LC-10AS instrument. The 
instrument was equipped with a two-solvent system allowing for the use of a gradient method of 
sample elution. The solvents were labeled Solvent A and Solvent B and were pumped into the 
column using separate solvent pumps A and B. The pumps were used to generate a maximum 
pressure of 5000 psi enabling the solvent and sample to move through the column. The range of 
solvent pressure which was used during the experiment was between 1200-4500 psi. The 
instrument was equipped with a SPD-10A UV-Vis detector which was set to 254 nm and 
allowed for the detection of organic analytes. The instrument was controlled through a SCL-
10AVP system controller to manage the time programs used throughout the study. Temperature 
was maintained at 25°C during all HPLC purification methods. 
 It was necessary for the HPLC-Grade solvents used throughout this study to undergo 
vacuum degassing to remove excess air within them. The formation of air bubbles during HPLC 
purification can cause problems with solvent delivery and analyte detection. Though some more 
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modern HPLC instruments are equipped with internal solvent degassers, it was necessary to 
undertake vacuum degassing of the solvents used in this study manually. This was accomplished 
by placing the solvents in a HPLC solvent container, adding a stir bar, and applying a vacuum to 
the container. The solvents were agitated under vacuum until all excess air had been removed.  
Reversed-phase high-performance liquid chromatography was used to effectively isolate 
the antimicrobial compound of interest. This method causes polar compounds to elute from the 
sample first while non-polar compounds are retained longer and elute later. To attain this type of 
separation the stationary phase of the HPLC column is typically a non-polar hydrophobic 
medium which will form associations with non-polar compounds found within the sample.36 The 
solvents which are used as the mobile phase for reversed-phase high-performance liquid 
chromatography are usually polar. This means that water is typically the “weakest” solvent 
because it repels highly hydrophobic compounds into the stationary phase causing longer 
retention times.36 A polar organic modifier is usually selected which is less polar than water, 
thereby making it a “stronger” solvent since it will no longer strongly repel the analyte into the 
stationary phase allowing it to move through the column more easily.36  
 To obtain greater separation of the constituents of the samples subjected to HPLC, a 
gradient method was used. This method utilizes the independent solvent pumps of the HPLC 
system to alter the ratio of each solvent in the mobile phase over time. By altering the mobile 
phase composition throughout the time program better separation of the constituents of the 
sample can be obtained, the time of separation can be significantly decreased, and column 
contamination can be eliminated. This method also ensures that all components of the sample are 
eluted decreasing sample loss.  
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 The columns selected for this study were chosen based on their favorable properties 
which increased separation of the sample and aided in increasing the efficiency of the 
purification method. A semi-preparative column was used for initial purification of the active 
fractions eluted through the Sephadex™ LH-20 column. A Hamilton polymeric reversed phase-1 
column was selected for the semi-preparative step. This column was packed with poly(styrene 
divinylbenzene) with particle sizes between 12 μm and 20 μm and a pore size of 100 Å. The 
inner diameter of the column was 21.2 mm and a length of 250 mm. Due to the larger particle 
size, the number of theoretical plates of the column decreases thus allowing for an increased 
mobile phase flow rate and a decreased solvent pressure. A Kinetex® phenyl-hexyl 100 Å 
analytical column was used for additional preparation prior to final HPLC purification. This 
column was packed with hexyl linked phenyl with trimethylsilyl endcapping with a particle size 
of 5 μm and a pore size of 100 Å. The column length was 250 mm and the internal diameter was 
4.6 mm. For the final purification of the antimicrobial compound, multiple rounds of HPLC were 
conducted using a Kinetex® 5 μm EVO C18 100 Å analytical column with a particle size of 5 
μm and a pore size of 100 Å. The internal diameter of this column was 4.6 mm and the length of 
it was 150 mm. Both of the Kinetex® analytical columns utilized core-shell technology in which 
a homogenous porous shell of stationary phase substrate envelops a non-porous compact silica 
core. Because the core is non-porous, less band broadening is observed leading to greater 
resolution between eluted compound peaks. Throughout the study a guard column obtained 
through Phenomenex (Torrance, CA) was utilized to remove dust and contaminants found within 
the solvent. This prevented damage to the HPLC instrument, eliminated the appearance of “ghost 
peaks”, and increased the purity of the antimicrobial compound. 
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 The solvents used as the HPLC mobile phase throughout this study were selected based 
on their suitability for reversed-phase high-performance liquid chromatography. The ideal 
solvents were water-miscible, low viscosity, chemically unreacted, demonstrated low UV 
absorbance, and good solubility properties. Based on polarity and solvent strength acetonitrile 
was chosen to be solvent B throughout most of the study while water was used as solvent A. 
Solvent buffers were also used occasionally throughout the study. 20 μM Ammonium formate 
was added to water during initial method development. Ammonium hydroxide was also used as a 
buffer in both water and acetonitrile at various times during HPLC purification to improve 
separation of sample constituents. Since the development of the HPLC method was partially 
based on a trial and error approach, different combinations of solvents and buffers were used 
until the desired purity was obtained. 
Semi-Preparative HPLC Elution Method 
 The extract obtained through Sephadex™ LH-20 column chromatography was subjected 
to initial HPLC purification through the Hamilton PRP-1 column. The solvents used were 
acetonitrile and water with no buffers added. Prior to injecting the sample, the column was 
equilibrated for 45 minutes with 80% solvent A (water) and 20% solvent B (acetonitrile) and a 
solvent flow rate of 4.00 mL/min. After the column had been equilibrated 1 mL of the sample 
was injected into the column. The flow rate was maintained at 4.00 mL/min throughout the time 
program. The initial solvent ratio of 80:20 was maintained for 3.20 minutes after which time the 
concentration of solvent B was gradually increased to 100% over the course of 60.20 minutes. 
The 100% concentration of solvent B was then maintained from 63.40 minutes until 93.40 
minutes at which time the time program was ended, and the column was washed with 100% 
acetonitrile for 30 minutes. All collected peaks were tested for activity and active peaks were 
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combined. The time program for the gradient elution method used during the semi-preparative 
stage is shown in Table 1.  
 
Table 1: HPLC solvent time program for semi-preparative and preparative HPLC purification steps. 
Preparative HPLC Elution Method 
 The combined active semi-preparative HPLC extract was then subjected to a preparative 
elution method which utilized the Kinetex® phenyl-hexyl 100 Å column. Prior to injection of the 
sample the column was equilibrated with a solvent ratio of 80% solvent A (water) and 20% 
solvent B (acetonitrile) for 45 minutes with a solvent flow rate of 2.00 mL/min. 500 μL of the 
sample was then injected into the column. The flow rate was maintained at 2.00 mL/min, and for 
3.20 minutes the solvent ratio was maintained at 80:20. Then the concentration of solvent B was 
increased gradually from 20% to 100% between 3.20 min and 63.40 min. The mobile phase was 
maintained at a concentration of 100% solvent B from 63.40 min until 83.40 min at which time 
the controller stopped the run. All peaks collected were tested for activity and fractions 
containing peaks which eluted at similar times were combined. The time program for preparative 
HPLC purification was the same as that in Table 1. 
Final HPLC Purification 
 
Time Module Action Value 
0.20 Controller Start  
3.20 Pumps Pump B Conc.  20 
 63.20  Pumps Pump B Conc. 100 
 93.20 Pumps Pump B Conc. 100 




 During the final purification of the antimicrobial compound peaks eluted during the 
preparative phase of purification which displayed activity against the indicator bacteria were 
subjected to multiple rounds of purification using the Kinetex® 5μm EVO C18 100 Å analytical 
column. The column was equilibrated using 30% solvent B (acetonitrile) and 70% solvent A 
(water) for 45 minutes with a flow rate of 2.00 mL/min before the sample was injected. After 
equilibration 200 μL of the sample was injected into the column. The flow rate was maintained at 
2.00 mL/min and the mobile phase concentration remained at 30% solvent B from starting until 
45.20 minutes after which time it was gradually increased to 100% solvent B from 45.20 min 
until 75.20 min. The solvent ratio was maintained at 100% solvent B until the controller stopped 
the run at 95.20 min. Fractions containing peaks which eluted at similar times during the final 
purification were combined and subjected to the same final purification method until desired 
purity was attained. The time program used during analytical HPLC purification is depicted in 
Table 2. 
 
Table 2: Solvent time program utilized during analytical HPLC purification of the compound. 
Structural Elucidation Methods 
 The methods used during the determination of the structure of the antimicrobial 
compound produced by Rhodococcus sp. MTM3W5.2 are outlined below.  
Spectroscopic Methods 
Time Module Action Value 
0.20 Controller Start  
3.20 Pumps Pump B Conc.  30 
 45.20  Pumps Pump B Conc.  30 
 75.20 Pumps Pump B Conc. 100 




 UV-Vis spectra were measured using a Carey 8454 UV-Vis spectrophotometer. The 
absorbance was measured by filling 1 mL quartz cuvettes with a path length of 1 cm with the 
compound dissolved in acetonitrile. The UV absorbance was recorded from wavelengths of 210 
nm to 400 nm. Acetonitrile was used as the blank against which the absorbance was determined.  
 High-resolution mass analysis was conducted using a Bruker maXis mass spectrometer. 
The purified compound was dissolved in a mixture of acetonitrile and water with a ratio of 50:50 
and 0.1% formic acid. The sample was ionized by electrospray ionization in positive mode and 







 The large batch RM broth cultures were successful in growing the Rhodococcus 
MTM3W5.2 bacteria, and under stagnant conditions where the bacteria were allowed to form a 
biofilm there was sufficient production of the active compound for purification and 
characterization. Using the method of n-butanol crude extraction was effective at extracting the 
antimicrobial compound. Each of the n-butanol extracts demonstrated antimicrobial activity 
against the sensitive indicator bacteria Rhodococcus erythropolis IGTS8. The crude extract was 
dried and reconstituted in isopropanol before subjecting it to Sephadex LH-20 column 
chromatography. The media phase of the RM broth culture was tested for activity after 
undergoing the second n-butanol extraction and did not demonstrate any antimicrobial activity. 
The zone inhibition plate obtained for the crude n-butanol extract is depicted in Figure 6. 
 
Figure 6: Zone inhibition plate of the crude n-butanol extract demonstrating the antimicrobial activity of 
the crude extract against the indicator bacteria. 
Sephadex LH-20 Chromatography 
 Sephadex™ LH-20 column chromatography was effective as a preliminary method of 




Sephadex column, impurities in the sample which were not a similar size to the antimicrobial 
compound were removed from the sample. Sephadex column chromatography was conducted on 
all crude extracts obtained during this study. Though there was some variation in the retention 
time of the active compound throughout the study, it was consistently eluted early during the 
preliminary Sephadex purification. The active Sephadex fractions were dried under a fume hood 
and combined using a minimum amount of methanol and isopropanol. The zone inhibition plates 
for the Sephadex LH-20 fractions obtained from the fractionation of the crude extract are shown 
in Figure 7. 
 
Figure 7: Zone inhibition plates for the Sephadex LH-20 extract demonstrating the activity of fractions 3, 
4, and 5 while all other fractions are inactive against the indicator bacteria. 
Semi-Preparative HPLC 
 The active Sephadex LH-20 extract was then subjected to semi-preparative high-
performance liquid chromatography. The solvents used were water (solvent A) and acetonitrile 
(solvent B). The column which was used was a Hamilton polymeric reversed phase-1 column. A 
gradient elution method was used to ensure good separation of the active compound was 
achieved. After injection of 1 mL of the Sephadex extract, the solvent ratio was maintained at 
20% solvent B until the 3.20-minute mark. The concentration of solvent B was then steadily 


















maintained at 100% solvent B until the end of the collection period at 93.40 minutes. Since 
multiple rounds of semi-preparative HPLC were conducted the fractions which eluted were 
tested for activity using zone inhibition assay and combined to undergo the preparative HPLC 
method. The active peaks which were eluted demonstrated a need for further purification of the 
compound due to the band broadness of the active peaks and the peak overlap that was observed. 
A representative chromatogram obtained during the semi-preparative HPLC purification step is 
shown in Figure 8 and demonstrates the band broadness and peak overlap which characterized 
much of the preliminary HPLC purification. The zone inhibition plates obtained from the 
representative chromatogram are shown in Figure 9.  
 
Figure 8: A chromatogram of the semi-preparative HPLC purification step depicting the peaks obtained 
from the active Sephadex extract. Numbers represent the peaks collected. 
 
Figure 9: The zone inhibition plates of the peaks obtained from the semi-preparative HPLC step 
































 The combined active semi-preparative fractions were subjected to preparative HPLC on a 
Kinetex® phenyl hexyl 100 Å analytical column using water and acetonitrile as the solvents. The 
preparative purification followed the time program outlined above using the gradient elution 
method described. Multiple rounds of preparative HPLC were conducted and activity was 
determined using zone inhibition assay. A representative chromatogram obtained during the 
preparative HPLC purification step is depicted in Figure 10. Due to the lack of peak resolution 
obtained during the preparative phase of HPLC purification, it was determined that further 
purification was necessary for structural elucidation methods to be effective. Using the program 
outlined above, peaks with antimicrobial activity were eluted between 38.15 minutes and 51.10 
minutes.  
 
Figure 10: Chromatogram obtained during preparative HPLC purification of the antimicrobial compound 
demonstrating the need for better peak resolution.  
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Analytical HPLC Purification 
 The combined active fractions obtained from the preparative HPLC method were then 
subjected to multiple rounds of analytical HPLC purification. The time program and solvents 
used during this phase of purification is depicted above. Analytical HPLC purification yielded 
two compounds of interest which eluted at differing times. The active antimicrobial compound of 
interest was eluted at approximately 58 minutes using the time method described above, while a 
second peak of interest was eluted at approximately 72 minutes. The peak eluted at 72 minutes 
did not demonstrate activity against the sensitive indicator bacteria. Both compounds were 
subjected to several rounds of analytical HPLC until a desired purity was obtained. A 
representative chromatogram of the peak eluted at 58 minutes is shown in Figure 11 while Figure 
12 depicts a chromatogram of the peak which was eluted at 72 minutes.  
 
Figure 11: A representative chromatogram of the final purification step of the active peak which eluted 




Figure 12: A representative chromatogram of the compound eluted at 72.77 minutes which depicts 
good resolution of the peak of interest.  
UV-Visible Spectrum 
 The purified compounds which were eluted at 58 minutes and 72 minutes during the 
analytical HPLC purification method were subjected to UV-Visible spectroscopy. The 
absorption of the compounds over a range of wavelength was measured using a UV-Visible 
spectrophotometer. The UV-Vis spectrum of the 58 minute compound depicts broad absorbance 
in the UV range with absorbance maxima at 277 nm and 327 nm. The UV-Vis spectrum of the 
58 compound is depicted in Figure 13. The UV-Vis spectrum of the compound which eluted at 
72 minutes likewise showed strong absorbance in the UV region. It had absorbance an maximum 




Figure 13: UV-Visible spectrum obtained for two different concentrations of the compound eluted at 
approximately 58 minutes with absorbance maxima at 277 nm and 327 nm. The blue line indicates a 
concentration of 160 µg/mL while the pink line indicates a concentration of 80 µg/mL. 
 
Figure 14: UV-Visible spectrum of the compound eluted at approximately 72 minutes at two different 
concentrations depicting an absorbance maximum at 242 nm. The red line indicates a concentration of 
160 µg/mL while the black line indicates a concentration of 80 µg/mL. 
High-Resolution Mass Spectrum 
 The antimicrobial compound of interest which were obtained from HPLC purification 
were subjected to high-resolution mass spectroscopy. The exact mass of the compound eluted at 
58 was found at m/z 911.5490 [M+H]+. The high-resolution mass spectrum which was obtained 
for this compound is depicted in Figure 15 with a full spectrum obtained from the sample along 
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with a zoomed isotope cluster for the molecular ion peak. The molecular formula for the 
compound was found to be C52H78O13. 
 
Figure 15: The high-resolution mass spectrum of the compound eluted at 58 minutes containing the full 
scan spectrum of the sample (a) and a zoomed isotope cluster for the molecular ion peak of the 






Extraction and Purification 
Crude Extraction 
Since n-butanol is immiscible in water it forms an organic layer above the aqueous media phase 
making extraction relatively simple via a separatory funnel. Because of the moderate polarity of 
the active antimicrobial compound, n-butanol was successful at extracting it while minimizing 
the extraction of other unwanted compounds of greater or lesser polarity. The aqueous media 
phase of the RM broth cultures was tested for activity against the sensitive indicator bacteria, and 
did not demonstrate any activity. This demonstrated the effectiveness of the crude n-butanol 
extraction method at obtaining the maximum amount of antimicrobial compound possible. Given 
the success of the RM broth culture method, several large batch cultures were created to obtain a 
more significant amount of the compound of interest. Throughout the study the large batch 
cultures were grown for at least 2 weeks; however, under conditions which the cultures could not 
be extracted due to time constraints, they were left for up to 3 weeks. Due to the volume of 
media contained within each Erlenmeyer flask the Rhodococcus MTM3W5.2 cultures grown for 
this extended period did not show evidence of entering into the death phase, and the 
antimicrobial compound was still present upon the n-butanol extraction. The n-butanol extract 
demonstrated antimicrobial activity from each of the large RM broth cultures allowing the 
cultures to be further purified.  
Sephadex Chromatography 
 Since the antimicrobial compound consistently eluted early during the Sephadex 
purification step, the relative size of the molecule can be determined. Based on the retention time 
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of the compound of interest, it can be determined that the compound is relatively large, too large 
to associate with most of the pores of the Sephadex media, causing it to pass through the column 
more quickly than the smaller molecules found in the crude extract. Sephadex LH-20 column 
chromatography was shown to be an efficient method of purification as there was minimal loss 
of the antimicrobial compound of interest.  
HPLC Purification 
 Based on the chromatograms obtained throughout the HPLC purification methods 
outline, it was determined that the final pure 58-minute compound and the 72-minute compound 
were sufficiently pure for spectral analysis. By obtaining a sharp peak with no detected overlap 
indicated by the presence of shoulders within the peak of interest it was determined that the 
reversed-phase high-performance liquid chromatography method which was employed was 
successful in purifying the compounds of interest. The compound eluted at 58 minutes was found 
to be moderately polar based on the retention time during RP-HPLC. This determination was 
based on the ability of the compound to associate with the stationary phase of the Kinetex® 5 
µm EVO C18 100 Å column early in the analytical HPLC time program, but was eluted before 
the mobile phase concentration had reached 100% acetonitrile during which more non-polar 
compounds were eluted. The compound eluted at 72 minutes was found to be less polar than the 
active antimicrobial compound as it associated with the stationary phase until the mobile phase 





 Based on the UV-Visible spectrum of the compound eluted at 58 minutes it was 
determined that conjugated systems were present within the compound. The strong absorbance in 
the UV range along with the absorbance maxima at 277 nm and 327 nm were indicative of the 
polyketide nature of the compound. Most polyketides produced by type I PKSs have small 
conjugated systems which exhibit absorbance in the UV region with bands of approximately 
230-300 nm.37 Since the absorbance of the compound and the maxima of the 58- minute 
compound is similar to those which are typical of polyketides, it is likely that the compound is a 
polyketide. The UV-Visible spectrum of the compound eluted at 72 minutes indicated the 
presence of some chromophores, and it may indicate some conjugation within the compound as 
well. The strong absorbance in the UV region indicates the compound has fewer conjugated 
systems than the compound eluted at 58 minutes. The absorbance maximum 242 nm indicates 
that it is less likely that the compound is a polyketide.  
High-Resolution Mass Spectrum 
 The high-resolution mass spectrum obtained for the 58 minute compound indicated that 
the molecular ion peak of the compound at m/z 911.5490 [M+H]+ corresponding to a molecular 
formula of C52H78O13. Based on the molecular formula obtained through ESI Time-of-Flight 
Mass Spectroscopy, it was determined that the compound exhibited a high degree of 
unsaturation. It was estimated that the degree of unsaturation of the compound was 14 based on 
Equation 1. This high degree of unsaturation is in agreement with the UV-Visible spectrum 
obtained for the compound as it indicates the presence of conjugated systems within the 
molecule. The exact mass which was determined for the compound was in agreement with the 
retention time of the compound during Sephadex LH-20 chromatography.  




Structural Fragments of the Compound 
 Based on work by the research group using 1-D nuclear magnetic resonance spectroscopy 
method such as, 1H NMR, 13C NMR, and 2-D nuclear magnetic resonance spectroscopy such as 
Heteronuclear Multiple-Bond Correlation, Correlation Spectroscopy, and Total Correlated 
Spectroscopy, several major fragments of the compound were constructed.17 The determination 
of several key spin systems using 1H-1H COSY which were used to construct the structural 
fragments. Correlations between hydrogen and carbons within the molecule was also determined 
using a 1H-13C NMBC spectrum. The major fragments which were determined by the PI and the 
research team are depicted in Figure 16. Each spin system is shown in a different color and 
arrows within the figure indicate the hydrogen-carbon correlations found within the 1H-13C 
HMBC spectrum. The fragments which were determined by the NMR data indicate that the 
molecule has a polyketide structure. 
 
Figure 16: Major fragments which were assigned based on the various spin systems obtained from the 





Conclusion and Future Work 
 Based on the results of this study it was found that the antimicrobial compound of interest 
may in fact have a novel polyketide structure; however, full structural identification will be 
necessary to determine whether the chemical scaffold of the compound is a novel scaffold. It was 
determined during this study that the method of RM broth extraction using n-butanol was 
effective at removing the antimicrobial compound from the RM broth, and that the purification 
method was effective in yielding a purified compound. By utilizing different HPLC time 
programs and adding modifiers based on the chromatogram obtained from the purification of the 
sample, an effective method of purification was established which caused minimal degradation 
to the compound. Due to low rates of the production of the antimicrobial compound spectral 
analysis by NMR was difficult, leading to NMR spectra which contained too much noise to 
elucidate the entirety of the compound of interest. However, based on the major fragments which 
were constructed from the spin systems obtained through 1H-1H COSY it was determined that 
the compound is a polyketide. It was also determined that the compound has a high degree of 
unsaturation—14—indicating the presence of the conjugated systems depicted in the fragment 
which were constructed. The molecular formula of the antimicrobial compound was found to be 
C52H78O13 with an exact mass of 911.5490.  
 The compound which was isolated at 72 minutes during the HPLC purification method 
was not found to be active against the indicator bacteria; however, due to the presence of the 
peak in preliminary analytical HPLC trials it was determined that the peak could be of some 
interest in determining the structure of the antimicrobial compound. Preliminary spectral results 
indicate that the compound contains less conjugated systems than the active compound and 
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further structural identification should be done to elucidate the structure of the 72-minute 
compound.  
Future Work 
 Because of the time constraints on this study the entire structure of the antimicrobial 
compound was not able to be elucidated. Further, only preliminary structural data was obtained 
for the compound which eluted at 72 minutes. To elucidate the final structure of the 
antimicrobial compound of interest it will be necessary for further production of the compound 
to be conducted using the method outlined above. Further purification of the compound will be 
necessary to obtain the spectral data required to determine the complete structure of the 
compound. Scaling up the production of the antimicrobial compound may also be necessary to 
obtain a compound concentration high enough to avoid the introduction of noise into the NMR 
spectra. Since the compound that eluted at 72 minutes may be helpful in determining the 
structure of the antimicrobial compound, structural elucidation should be undertaken for it as 
well. It will be necessary to obtain a high-resolution mass spectrum for the compound, and 
subject it to 1D and 2D NMR spectroscopy so that the molecular structure can be obtained. 
 Upon structural elucidation of the antimicrobial compound a bioactivity profile against a 
large library of bacteria should be constructed. This could give insight into the specificity of the 
compound and may help indicate its mechanism of action. By understanding the mechanism of 
action, it may be possible to determine the practicality of using the antimicrobial compound 
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